Attention Deficit Hyperactivity Disorder (ADHD) News and Research

RSS

Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral).

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.

24 May 2010

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

The prognosis for children born with severe acute asphyxia has improved in recent years owing to new clinical procedures and better diagnostics, according to a new doctoral thesis from the Swedish medical university Karolinska Institutet. By measuring levels of lactic acid in the blood during childbirth and the brain activity of the newborn afterwards, doctors can make a much more reliable assessment of the risk of serious brain damage.

21 May 2010

Drug trend for children increased 10.8% in 2009 across America

In growing numbers, children across America are adding a dose of medicine to their daily routine. In 2009, drug trend for children – a measure of prescription spending growth – increased 10.8 percent, driven by a 5 percent increase in drug utilization and higher medication costs, according to the Medco 2010 Drug Trend Report. The growth in prescription drug use among children was nearly four times higher than the rise seen in the overall population.

20 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Study demonstrates need for understanding societal, economic impact of growing medicalization

Menopause. Normal pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several decades, these conditions have come to be defined and treated as medical problems. They've been "medicalized." In the first study of its kind in the current issue of Social Science and Medicine, Brandeis researchers used national data to estimate the costs of these and a handful of other common conditions on escalating U.S. healthcare spending.

19 May 2010

Exosure to organophosphate pesticides associated with increased risk of ADHD in children

Following closely on the heels of the President's Cancer Panel Report exhorting consumers to choose food grown without pesticides or chemical fertilizers, antibiotics, and growth hormones to help decrease their exposure to environmental chemicals that can increase their risk of contracting cancer, a study published in today's issue of the journal Pediatrics concludes that exposure to organophosphate pesticides at levels common among U.S. children may contribute to the prevalence of attention deficit hyperactivity disorder in these children.

18 May 2010

Cortex first-quarter net income increases to $0.08 per share

Cortex Pharmaceuticals, Inc. reported net income of approximately $5,596,000, or $0.08 per share for the quarter ended March 31, 2010 compared with a net loss of $3,168,000, or $0.07 per share for the corresponding prior year period, with the difference reflecting revenues from the Company's March 2010 transaction with Biovail Laboratories International SRL (Biovail).

17 May 2010

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.

15 May 2010

Computerized model for treating nicotine addiction wins first place at ISEF science competition

A project using cutting edge computer modeling to identify potential new medications for nicotine addiction won first place distinction at the annual Addiction Science Awards at this year's Intel International Science and Engineering Fair (ISEF) --- the world's largest science competition for high school students.

15 May 2010

Gene variations may increase risk of developing schizophrenia: Study

By analyzing the genomes of patients with schizophrenia, genetics researchers have discovered numerous copy number variations—deletions or duplications of DNA sequences—that increase the risk of developing schizophrenia. Significantly, many of these variations occur in genes that affect signaling among brain cells.

11 May 2010

Researchers to identify rare genetic mutation to produce histamine against TS

A single, very unusual family with Tourette syndrome has led Yale School of Medicine researchers to identify a rare mutation in a gene that is required to produce histamine. The finding provides a new framework to understand many years of data on the role of histamine function in the brain and points to a potentially novel approach to treatment of tics and Tourette.

6 May 2010

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

Children with ADHD who carry a specific type of dopamine receptor gene respond better to the drug methylphenidate than those without the genotype, according to new research from Cincinnati Children's Hospital Medical Center.

4 May 2010

Maternal smoking during pregnancy increases risk of psychiatric problems in children

It is well-known that maternal smoking during pregnancy can have long-term effects on the physical health of the child, including increased risk for respiratory disease, ear infections and asthma. New research shows that prenatal smoking also can lead to psychiatric problems and increase the need for psychotropic medications in childhood and young adulthood.

4 May 2010

Play-based intervention trial at Sydney University for children with ADHD

The Sydney University Faculty of Health Sciences is seeking participants for a new play-based intervention program which aims to assist children with ADHD to develop their social interactions.

4 May 2010

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

Psychotropic medications common among children with ASD: Research

Behavioral interventions typically are the first line of treatment to manage unwanted behaviors in children with autism spectrum disorders. If behaviors do not improve, medications frequently are added to the mix.

3 May 2010

Children living in kinship care experience a multitude of health issues

It is well-known that children in foster care are at increased risk for physical and mental health problems. But what about kids who live with relatives other than their birth parents?

3 May 2010

Free groups available for socially vulnerable children

Free groups for socially vulnerable children aged 8 to 12 are available through Fairleigh Dickinson University. These groups, which are part of a research program, are ongoing and consist of either 10 weekly group sessions emphazing anxiety reduction and changing misperceptions or 10 weekly group sessions emphasizing the application of broad-based social skills.

27 Apr 2010

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision by the U.S. District Court of Delaware that the patent for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation.

27 Apr 2010

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Further Reading

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

Drug trend for children increased 10.8% in 2009 across America

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Study demonstrates need for understanding societal, economic impact of growing medicalization

Exosure to organophosphate pesticides associated with increased risk of ADHD in children

Cortex first-quarter net income increases to $0.08 per share

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Computerized model for treating nicotine addiction wins first place at ISEF science competition

Gene variations may increase risk of developing schizophrenia: Study

Researchers to identify rare genetic mutation to produce histamine against TS

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

Maternal smoking during pregnancy increases risk of psychiatric problems in children

Play-based intervention trial at Sydney University for children with ADHD

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Psychotropic medications common among children with ASD: Research

Children living in kinship care experience a multitude of health issues

Free groups available for socially vulnerable children

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News